New York

New York has several live policy models competing at once. The medical model sits in A2142A/S5303A. The narrower pilot model for veterans and first responders sits in S1801A/A3845A. The broader natural-hallucinogen reform model sits in A628. That breadth matters because it shows the debate is no longer only about research; it is about programme design, target population, and the boundary between public health access and decriminalisation.###

Legislative scrutiny intensified in late 2025. Assembly Health Chair Amy Paulin held a public hearing in New York City on 30 Sep 2025 examining the medicinal value and risks of psilocybin. That hearing did not itself create access, but it moved psychedelics from fringe bill filing into formal committee-level health policy discussion.###

New York is the strongest research state in this set. NYU Langone’s Center for Psychedelic Medicine is running or advertising multiple psychedelic clinical trials, including psilocybin work in major depressive disorder and smoking cessation, and NYU-related trial materials show New York locations in Usona’s phase 3 MDD programme.###

Mount Sinai’s psychedelic centre, now expanded and renamed the Parsons Research Center for Psychedelic Healing, reports ongoing work spanning MDMA, psilocybin, and ketamine, and Mount Sinai is recruiting a ketamine-assisted psychotherapy trial for depression. The Bronx VA/Mount Sinai network is also visible in registry and institutional sources through MDMA studies for PTSD and psilocybin-assisted therapy for intergenerational trauma.###

Because New York has not enacted a psilocybin access law, implementation machinery is still bill text rather than operational reality. The most developed current proposal, S1801A, would put the pilot inside a state-administered, federally compliant structure and contemplates SUNY academic health centres developing a training programme informed by pilot outcomes.###

That means the state’s current implementation strength is indirect: New York already has the academic, clinical, ethics, and training institutions that could support a future programme. But no regulator has yet been verified as writing licensing rules, certifying facilitators, or authorising service centres for psilocybin outside research.###

The ecosystem is exceptionally strong on the research and training side. NYU Langone and Mount Sinai are national anchors. Columbia University School of Social Work launched a psychedelic-assisted therapy training track within its degree structure in fall 2024. That gives New York one of the deepest academic/workforce bases in the country even without enacted state access.###

For patient-access researchers and industry observers, New York is therefore a state where evidence generation and professional formation are ahead of regulation. The mismatch matters: the ecosystem can support future implementation, but patients still largely depend on trial participation, lawful ketamine/esketamine care, or eventual legislative change.###

Over the next 12 to 24 months, New York’s most likely developments are legislative rather than administrative. The main question is whether lawmakers choose the narrower veterans/first-responders pilot, the broader medical programme, or neither. Because New York already has strong academic and hospital infrastructure, any enacted bill could probably move faster from statute to implementation than in a state building capacity from scratch.###

Even so, reimbursement and real patient access would remain complicated. SPRAVATO already has a Medicaid pathway, but no equivalent psilocybin coverage mechanism is in force. The near-term watch items are committee movement on A2142A/S5303A and S1801A/A3845A, plus any shift from hearing-based discussion to appropriations and agency directives.###